Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ramipril
Drug ID BADD_D01909
Description Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Ramipril may be used in the treatment of hypertension, congestive heart failure, nephropathy, and to reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events.
Indications and Usage For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. [FDA Label] To reduce the rate of death, myocardial infarction and stroke in individuals at high risk of cardiovascular events. May be used to slow the progression of renal disease in individuals with hypertension, diabetes mellitus and microalubinuria or overt nephropathy. [T116]
Marketing Status approved
ATC Code C09AA05
DrugBank ID DB00178
KEGG ID D00421
MeSH ID D017257
PubChem ID 5362129
TTD Drug ID D01STB
NDC Product Code 76282-671; 53104-7573; 50090-5730; 50090-5947; 57237-225; 62135-273; 63629-1254; 65841-701; 65862-475; 68180-590; 70518-3038; 71205-029; 65862-476; 57237-222; 60760-476; 61570-111; 62135-274; 68001-429; 0054-0108; 71335-1057; 51655-904; 63187-277; 65841-656; 65841-657; 65841-700; 65841-702; 62135-271; 63187-073; 65841-699; 65862-477; 0054-0106; 68382-145; 68382-147; 68382-376; 71335-0894; 71335-1056; 76282-672; 55111-057; 16729-152; 50090-4691; 51655-296; 61570-110; 63187-816; 68382-146; 82348-101; 16729-153; 45865-441; 51655-347; 51655-406; 61570-112; 63187-644; 65841-655; 65841-658; 68180-589; 68382-144; 70518-1200; 76282-670; 17404-1021; 16729-154; 50090-5673; 60760-571; 63187-854; 63187-915; 0054-0109; 68382-375; 65862-320; 65862-474; 68554-0004; 51655-346; 60760-481; 62135-272; 68001-428; 0054-0107; 68180-591; 71205-080; 58032-0123; 16729-155; 45865-443; 51655-975; 68001-430; 68001-431; 71335-9645; 76282-673; 69037-0051; 61570-120; 68382-374; 68382-377; 15308-0300; 57237-223; 57237-224
UNII L35JN3I7SJ
Synonyms Ramipril | Vesdil | Triatec | Altace | Zabien | Ramace | Tritace | Acovil | Delix | Carasel | HOE-498 | HOE 498 | HOE498
Chemical Information
Molecular Formula C23H32N2O5
CAS Registry Number 87333-19-5
SMILES CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N2C3CCCC3CC2C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Left ventricular dysfunction02.04.02.0110.000186%
Balance disorder08.01.03.081; 17.02.02.0070.001399%Not Available
Idiosyncratic drug reaction08.06.01.0020.000186%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.000093%Not Available
Dysstasia15.03.05.011; 17.02.02.012; 08.01.03.0890.000093%Not Available
Lupus-like syndrome10.04.03.003; 23.03.02.004; 15.06.02.0040.000140%Not Available
Musculoskeletal chest pain22.09.01.001; 15.03.04.0120.000280%
Blood pressure inadequately controlled24.06.01.0070.000569%Not Available
Exercise tolerance decreased08.01.03.036--Not Available
Systemic inflammatory response syndrome24.06.03.008; 10.02.01.008; 08.01.05.0050.000093%Not Available
Rhinalgia22.12.03.0200.000093%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000140%Not Available
Conjunctival hyperaemia06.04.01.0040.000093%Not Available
Metabolic syndrome14.06.02.007; 05.06.02.007; 24.08.02.0140.000093%Not Available
Ear discomfort04.03.01.0050.000326%Not Available
Eye pruritus06.04.05.0060.000186%Not Available
Lymphatic disorder01.09.01.003--Not Available
Drug tolerance08.06.01.0030.000093%Not Available
Cardiac flutter02.03.02.0120.000093%Not Available
Oral pruritus07.05.05.0020.000186%Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.0040.000140%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.0010.000233%Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
Limb deformity15.10.03.0040.000280%Not Available
Cerebral haematoma24.07.04.006; 17.08.01.0140.000140%Not Available
Affect lability19.04.01.0010.000186%Not Available
Foetal death18.01.02.003; 08.04.01.0110.000420%
Faecaloma07.01.03.0040.000093%Not Available
The 18th Page    First    Pre   18 19 20 21 22    Next   Last    Total 23 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene